Overview
Liming Zhao practices practicing medicine in Zhengzhou, China.
Zhao is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Moyamoya Disease, Pica, Stroke, and Carotid Artery Disease.
They are actively involved in clinical research, co-authoring 18 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Liming Zhao
Is Liming Zhao a top-rated expert for Moyamoya Disease?
MediFind is an objective health platform that identifies experts based on real-world data. Liming Zhao is classified as an Advanced expert for Moyamoya Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Liming Zhao participate in research or clinical trials?
Yes. Liming Zhao has published 18 articles and abstracts on conditions like Moyamoya Disease. You can view a list of Liming Zhao's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Moyamoya DiseaseZhao isAdvanced. Learn about Moyamoya Disease.
- Experienced
- Carotid Artery DiseaseZhao isExperienced. Learn about Carotid Artery Disease.
- PicaZhao isExperienced. Learn about Pica.
- StrokeZhao isExperienced. Learn about Stroke.